Duchenne-izomdisztrófia: vizsgálatok itt: Hollandia

In Hollandia 12 Also abroad 87

12 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 12.. Ask the study team whether a trial fits you.

3. fázisTaking people
A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpacibart Zotadirsen) in Participants With DMD With Gene Mutations Amenable to Exon 44 Skipping
Where
Leiden
Életkor
7 év to 16 év
People
70 worldwide
Run by
Avidity Biosciences, Inc.
See details and how to joinNCT07587242
3. fázisTaking people
Study in which all the patients take the same investigational drug with the aim of evaluate the long-term safety, tolerability, and efficacy of GIVINOSTAT in all the patients affected with Duchenne Muscolar Dystrophy who have been already treated in one of the GIVINOSTAT studies in the past
Where
Leiden, Nijmegen
Életkor
Up to 64 év
People
207 worldwide
Run by
Italfarmaco S.p.A.
See details and how to join2023-504520-26-00 · EU 2023-504520-26-00
2. fázisTaking people
A Phase 2 Open-label (Core Phase Plus Extension Phase) With 2 Cohorts Study to Assess the Pharmacokinetics and Safety of Givinostat in DMD Patients Ages From at Least 2 Years to Less Than 6 Years Old
Where
Leiden
Életkor
Up to 17 év
People
10 worldwide
Run by
Italfarmaco S.p.A.
See details and how to join2024-511823-32-00 · EU 2024-511823-32-00
3. fázisTaking people
A Study of SGT-003 Gene Therapy in Ambulant Males With Duchenne Muscular Dystrophy (IMPACT DUCHENNE)
Where
Leiden
Életkor
7 év to 11 év
People
80 worldwide
Run by
Solid Biosciences Inc.
See details and how to joinNCT07160634 · EU 2025-522949-22-00
2. fázisCsak meghívásos
Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy
Where
Leiden
People
260 worldwide
Run by
Edgewise Therapeutics, Inc.
See details and how to joinNCT06066580
1/2. fázisTaking people
A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping to Evaluate the Safety and Efficacy of ENTR-601-45
Where
Leiden, Nijmegen
Életkor
4 év to 20 év
People
24 worldwide
Run by
Entrada Therapeutics, Inc.
See details and how to joinNCT07038824 · EU 2024-517499-39-00
3. fázisTaking people
Efficacy, Safety and Tolerability of Givinostat in Non-ambulant Patients With Duchenne Muscular Dystrophy
Where
Leiden, Nijmegen
Életkor
9 év to 17 év
People
138 worldwide
Run by
Italfarmaco
See details and how to joinNCT05933057 · EU 2023-503521-19-00
2. fázisCsak meghívásos
An Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of BMN 351 in Participants With Duchenne Muscular Dystrophy
Where
Leiden
Életkor
4 év to 64 év
People
18 worldwide
Run by
BioMarin Pharmaceutical
See details and how to joinNCT07573631 · EU 2024-511656-41-00
2. fázisNot yet taking people in Hollandia
Long-Term Extension Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon Skipping to Evaluate the Safety and Efficacy of Endosomal Escape Vehicle Phosphorodiamidate Morpholino Oligomer Platform Products (ELEVATE-LTE)
Where
Leiden, Nijmegen
Életkor
4 év to 20 év
People
80 worldwide
Run by
Entrada Therapeutics, Inc.
See details and how to joinNCT07682129 · EU 2025-525124-10-00
3. fázisTaking people
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Global Study with an Open-Label Extension to Evaluate the Efficacy and Safety of Intravenous AOC 1044 (delpacibart zotadirsen) for the Treatment of DMD with Gene Mutations Amenable to Exon 44 Skipping
Where
Leiden
Életkor
Up to 17 év
People
42 worldwide
Run by
Avidity Biosciences Inc.
See details and how to join2025-523087-20-00 · EU 2025-523087-20-00
2/3. fázisTaking people
Givinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability Study
Where
Leiden, Nijmegen
Életkor
7 év and over
People
206 worldwide
Run by
Italfarmaco
See details and how to joinNCT03373968
2. fázisTaking people
Pharmacokinetics and Safety of Givinostat in DMD Patients Ages From at Least 2 Years to Less Then 6 Years Old
Where
Leiden
Életkor
2 év to 6 év
People
18 worldwide
Run by
Italfarmaco
See details and how to joinNCT06769633